Cyclic AMP enhancers and Aβ oligomerization blockers as potential therapeutic agents in Alzheimer's disease

Current Alzheimer Research

Volumn 4, Issue 3, 2007, Pages 263-271

  De Felice, Fernanda G ^a,b   Wasilewska Sampaio, Ana Paula ^a   Barbosa, Anna Carolina A P ^a   Gomes, Flavia C A ^a   Klein, William L ^b   Ferreira, Sérgio T ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENOL; AMYLOID BETA PROTEIN[25-35]; CYCLIC AMP; CYCLIC AMP DERIVATIVE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; NEUROTOXIN; TAU PROTEIN; TRANSCRIPTION FACTOR; AMYLOID BETA PROTEIN; SECRETASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; CONTROLLED STUDY; HUMAN; LONG TERM MEMORY; MEMORY; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NERVE FIBER GROWTH; NERVE REGENERATION; NEUROLOGIC DISEASE; NEUROTOXICITY; OLIGOMERIZATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM;

2,4-DINITROPHENOL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION; HUMANS; TAU PROTEINS;

EID: 34347383723     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507781077287     Document Type: Review

References (85)

1. Sutherland EW and Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem 232:1077-1091 (1958).
2. Rall TW and Sutherland EW. Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem 232:1065-1076 (1958).
3. Kresge N, Simoni RD, and Hill RL. Earl W. Sutherland's Discovery of Cyclic Adenine Monophosphate and the Second Messenger System. J Biol Chem 280: 39 (2005).
4. Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science 294: 1030-1038 (2001).
5. Byrne JH and Kandel ER. Presynaptic facilitation revisited: state and time dependence. J Neurosci 16: 425-435 (1996).
6. Bailey CH, Bartsch D and Kandel ER. Toward a molecular definition of long-term memory storage. Proc Natl Acad Sci USA 93: 13445-13452 (1996).
7. Ferreira ST, De Felice FG and Chapeaurouge A. Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins. Cell Biochem Biophys 44: 539-548 (2006).
8. Klein WL, Krafft GA and Finch CE. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24: 219-224 (2001).
9. Caughey B and Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26: 267-298 (2003).
10. Walsh DM and Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11: 213-228 (2004).
11. Klein WL. Synaptic targeting by Abeta oligomers (ADDLs) as a basis for memory loss in early AD. Alzheimer's & Dementia. In press (2006).
12. Sanchez S, Jimenez C, Carrera AC, Diaz-Nido J, Avila J and Wandosell F. A cAMP-activated pathway, including PKA and PI3K, regulates neuronal differentiation. Neurochem Int 44: 231-242 (2004).
13. Hernandez A, Kimball B, Romanchuk G and Mulholland MW. Pituitary adenylate cyclase-activating peptide stimulates neurite growth in PC12 cells. Peptides 16: 927-932 (1995).
14. Vaudry D, Chen Y, Ravni A, Hamelink C, Elkahloun AG and Eiden LE. Analysis of the PC12 cell transcriptome after differentiation with pituitary adenylate cyclase-activating polypeptide (PACAP). J Neurochem 83:1272-1284 (2002).
15. Ji Y, Pang PT, Feng L and Lu B. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci. 8: 164-72 (2005).
16. Ivins JK, Parry MK and Long DA. A novel cAMP-dependent pathway activates neuronal integrin function in retinal neurons. J Neurosci 24:1212-1216 (2004).
17. Wasilewska-Sampaio AP, Silveira MS, Holub O, Goecking R, Gomes FC, Neto VM, et al. Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound. FASEB J 19: 1627-1636 (2005).
18. Dumaz N and Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signaling pathways. FEBS J 272: 3491-3504 (2005).
19. Vossler MR, Yao H, York RD, Pan MG, Rim CS and Stork PJ. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89: 73-82 (1997).
20. Vaudry D, Stork PJ, Lazarovici P and Eiden LE. Signaling pathways for PC12 cell differentiation: making the right connections. Science 296: 1648-1649 (2002).
21. 2A receptor-induced neuronal differentiation in neuroblastoma cells and striatal primary cultures. J Neurochem 92: 337-348 (2005).
22. Chierzi S, Ratto GM, Verma P and Fawcett JW. The ability of axons to regenerate their growth cones depends on axonal type and age, and is regulated by calcium, cAMP and ERK. Eur J Neurosci 21: 2051-2062 (2005).
23. Luo L. Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annu Rev Cell Dev Biol 18: 601-635 (2002).
24. Weingarten MD, Lockwood AH, Hwo SY and Kirschner MW. A protein factor essential for microtubule assembly. Proc Natl Acad Sci USA 72: 1858-1862 (1975).
25. Drubin DG and Kirschner MW. Tau protein function in living cells. J Cell Biol 103: 2739-2746 (1986).
26. Avila J, Lucas JJ, Perez M and Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 84: 361-384 (2004).
27. Benitez-King G, Ramirez-Rodriguez G, Ortiz L and Meza I. The neuronal cytoskeleton as a potential therapeutic target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 3: 515-533 (2004).
28. Avila J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett 580: 2922-2927 (2006).
29. Li H, Li SH, Johnston H, Shelbourne PF and Li XJ. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25: 385-389 (2000).
30. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298: 789-791 (2002).
31. Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251-259 (2006).
32. Scheff SW and Price DA Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol Aging 24: 1029-1046 (2003).
33. Jacobs WB and Fehlings MG. The molecular basis of neural regeneration. Neurosurgery 53: 943-948 (2003).
34. Lu P, Yang H, Jones LL, Filbin M T and Tuszynski MH. Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury. J Neurosci 24: 6402-6409 (2004).
35. Teng FY and Tang BL. Axonal regeneration in adult CNS neurons-signaling molecules and pathways. J Neurochem 96: 1501-1508 (2006).
36. Song HJ, Ming GL and Poo MM. cAMP-induced switching in turning direction of nerve growth cones. Nature 388: 275-179 (1997).
37. Song H, Ming G, He Z, Lehmann M, McKerracher L, Tessier-Lavigne M, et al. Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides. Science 281: 1515-1518 (1998).
38. Cai D, Qiu J, Cao Z, McAtee M, Bregman BS and Filbin MT. Neuronal cyclic AMP controls the developmental loss in ability of axons to regenerate. J Neurosci 21: 4731-4739 (2001).
39. Gao Y, Deng K, Hou J, Bryson JB, Barco A, Nikulina E, et al. Activated CREB is sufficient to overcome inhibitors in myelin and promote spinal axon regeneration in vivo. Neuron 44: 609-621 (2004).
40. Bhatt DH, Otto SJ, Depoister B and Fetcho JR. Cyclic AMP-induced repair of zebrafish spinal circuits. Science 305: 254-258 (2004).
41. Harper JM, Krishnan C, Darman JS, Deshpande DM, Peck S, Shats I, et al. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci USA 101: 7123-7128 (2004).
42. Nikulina E, Tidwell JL, Dai HN, Bregman BS and Filbin MT. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci USA 101: 8786-8790 (2004).
43. Pearse DD, Pereira FC, Marcillo AE, Bates ML, Berrocal YA, Filbin MT, et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med 10: 610-616 (2004).
44. Kandel ER, Brunelli M, Byrne J and Castellucci V, Cold Spring Harbor Symp Quant Biol 40: 465 (1976).
45. Klein M and Kandel ER. Mechanism of calcium current modulation underlying presynaptic facilitation and behavioral sensitization in Aplysia. Proc Natl Acad Sci USA 77: 6912-6916 (1980)
46. Dash PK, Hochner B and Kandel ER. Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature 345: 718-721 (1990).
47. Bartsch D, Casadio A, Karl KA, Serodio P and Kandel ER. CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation. Cell 95: 211-223 (1998).
48. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Martin Villalba A, et al. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 31: 47-54 (2002).
49. Monti B, Berteotti C and Contestabile A. Subchronic rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 31: 278-286 (2006).
50. Wang H, Ferguson GD, Pineda VV, Cundiff PE and Storm DR. Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP. Nat Neurosci 7:635-642 (2004).
51. Aujla H and Beninger RJ. Hippocampal-prefrontocortical circuits: PKA inhibition in the prefrontal cortex impairs delayed nonmatching in the radial maze in rats. Behav Neurosci. 115: 1204-1211 (2001).
52. Jay TM. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol. 69: 375-390 (2003).
53. Pittenger C and Kandel ER. In search of general mechanisms for long-lasting plasticity: Aplysia and the hippocampus. Philos Trans R Soc Lond B Biol Sci 358: 757-763 (2003).
54. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453 (1998).
55. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100: 10417-10422 (2003).
56. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 24: 10191-10200 (2004).
57. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924: 133-140 (2002).
58. De Felice FG, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio E, et al. Alzheimer's disease-type tau hyperphosphorylation in hippocampal neurons induced by ADDLs submitted (2006).
59. Tong L, Thornton PL, Balazs R and Cotman CW. Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem 276: 17301-17306 (2001).
60. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH and Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21: 4125-4133 (2001).
61. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O and Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99:13217-13221 (2002).
62. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M and Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114: 1624-1634 (2004).
63. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A and Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP- responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25: 6887-6897 (2005).
64. Makhinson M, Opazo P, Carlisle HJ, Godsil B, Grant SG and O'dell TJ. A novel role for cyclic guanosine 3′,5′monophosphate signaling in synaptic plasticity: A selective suppressor of protein kinase A-dependent forms of long-term potentiation. Neuroscience 140: 415-431 (2006).
65. Matsuzaki K, Yamakuni T, Hashimoto M, Haque AM, Shido O, Mimaki Y, et al. Nobiletin restoring beta-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neurosci Lett 400: 230-234 (2006).
66. Kim SH, Nairn AC, Cairns N and Lubec G. Decreased levels of ARPP-19 and PKA in brains of Down syndrome and Alzheimer's disease. J Neural Transm Suppl 61: 263-272 (2001).
67. Yamamoto M, Gotz ME, Ozawa H, Luckhaus C, Saito T, Rosler M, et al. Hippocampal level of neural specific adenylyl cyclase type I is decreased in Alzheimer's disease. Biochim Biophys Acta 1535: 60-68 (2000).
68. Nishino N, Kitamura N, Hashimoto T and Tanaka C. Transmembrane signaling systems in the brain of patients with Parkinson's disease. Rev Neurosci 4: 213-222 (1993).
69. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 12: 497-508 (2003).
70. Sugars KL, Brown R, Cook LJ, Swartz J and Rubinsztein DC. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 279: 4988-4999 (2004).
71. Dobson CM. An accidental breach of a protein's natural defenses. Nat Struct Mol Biol 13: 295-297 (2006).
72. Klein WL, Lacor PN, De Felice FG and Ferreira ST Molecules that disrupt memory circuits in Alzheimer's disease: the attack on synapses by Aβ oligomers (ADDLs). Foundation Ipsen in press (2006).
73. De Felice FG, Houzel JC, Garcia-Abreu J, Louzada PR Jr, Afonso RC, Meirelles MN, et al. Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. FASEB J 15: 1297-1299 (2001).
74. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J. 18: 1366-1372 (2004).
75. De Felice FG and Ferreira ST. Novel neuroprotective, neuritogenic and anti-amyloidogenic properties of 2,4-dinitrophenol: The gentle face of Janus. IUBMB Life 58: 185-191 (2006).
76. Wang Z, Chang L, Klein WL, Thatcher GR and Venton DL. Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J Med Chem 47: 3329-3333 (2005).
77. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901 (2005).
78. Vieira MN, Figueroa-Villar JD, Meirelles MN, Ferreira ST and De Felice FG. Small molecule inhibitors of lysozyme amyloid aggregation. Cell Biochem Biophys 44: 549-553 (2006).
79. Raghu P, Reddy GB and Sivakumar B. Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. Arch Biochem Biophys 400: 43-47 (2002).
80. Cardoso I, Merlini G and Saraiva MJ. 4′-iodo-4′- deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J 17: 803-809 (2003).
81. Morais-de-Sa E, Neto-Silva RM, Pereira PJ and Saraiva MJ, Damas AM. The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin. Acta Crystallogr D Biol Crystallogr 62:512-519 (2006).
82. Barco A, Pittenger C and Kandel ER. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin Ther Targets 7: 101-114 (2003).
83. Carlezon WA Jr, Duman RS and Nestler EJ. The many faces of CREB. Trends Neurosci 28: 436-445 (2005).
84. Barad M, Bourtchouladze R, Winder DG, Golan H and Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 95:15020-15025 (1998).
85. Holub O and Ferreira ST Quantitative histogram analysis of images. Comp Phys Commun 175: 620-623 (2006).